Semi-parametric modeling of SARS-CoV-2 transmission in Orange County, California using tests, cases, deaths, and seroprevalence data (preprint)

Mechanistic modeling of SARS-CoV-2 transmission dynamics and frequently estimating model parameters using streaming surveillance data are important components of the pandemic response toolbox. However, transmission model parameter estimation can be imprecise, and sometimes even impossible, because surveillance data are noisy and not informative about all aspects of the mechanistic model. To partially overcome this obstacle, we propose a Bayesian modeling framework that integrates multiple surveillance data streams. Our model uses both SARS-CoV-2 diagnostics test and mortality time series to estimate our model parameters, while also explicitly integrating seroprevalence data from cross-sectional studies. Importantly, our data generating model for incidence data takes into account changes in the total number of tests performed. We model transmission rate, infection-to-fatality ratio, and a parameter controlling a functional relationship between the true case incidence and the fraction of positive tests as time-varying quantities and estimate changes of these parameters nonparameterically. We apply our Bayesian data integration method to COVID-19 surveillance data collected in Orange County, California between March, 2020 and March, 2021 and find that 33-62% of the Orange County residents experienced SARS-CoV-2 infection by the end of February, 2021. Despite this high number of infections, our results show that the abrupt end of the winter surge in January, 2021, was due to both behavioral changes and a high level of accumulated natural immunity.

[1]  N. Jewell,et al.  Mobility trends provide a leading indicator of changes in SARS-CoV-2 transmission , 2020, medRxiv.

[2]  Zunyou Wu,et al.  Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. , 2020, JAMA.

[3]  Pierre Del Moral,et al.  Stochastic Epidemic Models inference and diagnosis with Poisson Random Measure Data Augmentation. , 2020, Mathematical biosciences.

[4]  C. Newcomer,et al.  Quick Facts , 2020, General Pediatrics Board Review.

[5]  S. Bartell,et al.  Estimated seroprevalence of SARS-CoV-2 antibodies among adults in Orange County, California , 2020, Scientific Reports.

[6]  Sean C. Anderson,et al.  Quantifying the impact of COVID-19 control measures using a Bayesian model of physical distancing , 2020, PLoS Comput. Biol..

[7]  Simon Cauchemez,et al.  Likelihood-based estimation of continuous-time epidemic models from time-series data: application to measles transmission in London , 2008, Journal of The Royal Society Interface.

[8]  S. Eubank,et al.  Commentary on Ferguson, et al., “Impact of Non-pharmaceutical Interventions (NPIs) to Reduce COVID-19 Mortality and Healthcare Demand” , 2020, Bulletin of Mathematical Biology.

[9]  Andrew Gelman,et al.  General methods for monitoring convergence of iterative simulations , 1998 .

[10]  P. van den Driessche Spatial Structure: Patch Models , 2008, Mathematical Epidemiology.

[11]  Vladimir N. Minin,et al.  A linear noise approximation for stochastic epidemic models fit to partially observed incidence counts , 2020 .

[12]  D. Brodie,et al.  Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York City: a prospective cohort study , 2020, The Lancet.

[13]  C. Agrati,et al.  Immunological and inflammatory profiles in mild and severe cases of COVID-19 , 2020, Nature Communications.

[14]  N. Kantas,et al.  Key epidemiological drivers and impact of interventions in the 2020 SARS-CoV-2 epidemic in England , 2021, Science Translational Medicine.

[15]  Michael Höhle,et al.  Bayesian nowcasting during the STEC O104:H4 outbreak in Germany, 2011 , 2014, Biometrics.

[16]  S. Szpunar,et al.  Predictors for Severe COVID-19 Infection , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[17]  L. Brammer,et al.  Risk Factors for Intensive Care Unit Admission and In-hospital Mortality among Hospitalized Adults Identified through the U.S. Coronavirus Disease 2019 (COVID-19)-Associated Hospitalization Surveillance Network (COVID-NET) , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[18]  T. Stadler,et al.  Practical considerations for measuring the effective reproductive number, Rt , 2020, medRxiv.

[19]  Axel Gandy,et al.  Semi-Mechanistic Bayesian Modeling of COVID-19 with Renewal Processes. , 2020, 2012.00394.

[20]  Carl A. B. Pearson,et al.  Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England , 2021, Science.

[21]  Fred Brauer,et al.  Continuous-Time Age-Structured Models in Population Dynamics and Epidemiology , 2008 .

[22]  G. Marion,et al.  Using model-based proposals for fast parameter inference on discrete state space, continuous-time Markov processes , 2015, Journal of The Royal Society Interface.

[23]  Nicholas G. Polson,et al.  Tracking Epidemics With Google Flu Trends Data and a State-Space SEIR Model , 2012, Journal of the American Statistical Association.

[24]  D. Brodie,et al.  Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York City: a prospective cohort study , 2020, medRxiv.

[25]  A. Doucet,et al.  Particle Markov chain Monte Carlo methods , 2010 .

[26]  Oliver Stoner,et al.  Multivariate hierarchical frameworks for modeling delayed reporting in count data , 2019, Biometrics.

[27]  C. Whittaker,et al.  Report 9: Impact of non-pharmaceutical interventions (NPIs) to reduce COVID19 mortality and healthcare demand , 2020 .

[28]  Carl A. B. Pearson,et al.  The effect of control strategies to reduce social mixing on outcomes of the COVID-19 epidemic in Wuhan, China: a modelling study , 2020, The Lancet Public Health.

[29]  N. G. Davies,et al.  Effects of non-pharmaceutical interventions on COVID-19 cases, deaths, and demand for hospital services in the UK: a modelling study , 2020, The Lancet Public Health.

[30]  S. Preston,et al.  Assessing the Impact of the Covid-19 Pandemic on US Mortality: A County-Level Analysis , 2020, medRxiv.

[31]  Forrest W. Crawford,et al.  One year of modeling and forecasting COVID-19 transmission to support policymakers in Connecticut , 2020, medRxiv.

[32]  K. Bhaskaran,et al.  Severity of Severe Acute Respiratory System Coronavirus 2 (SARS-CoV-2) Alpha Variant (B.1.1.7) in England , 2021, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[33]  M. Plummer,et al.  CODA: convergence diagnosis and output analysis for MCMC , 2006 .

[34]  Adrian E. Raftery,et al.  Estimating SARS-CoV-2 infections from deaths, confirmed cases, tests, and random surveys , 2021, Proceedings of the National Academy of Sciences.

[35]  Aaron A. King,et al.  Time series analysis via mechanistic models , 2008, 0802.0021.

[36]  E. Ionides,et al.  Compound Markov counting processes and their applications to modeling infinitesimally over-dispersed systems , 2010, 1003.0173.

[37]  S. Pei,et al.  Burden and characteristics of COVID-19 in the United States during 2020 , 2021, Nature.

[38]  B. Finkenstädt,et al.  Statistical Inference in a Stochastic Epidemic SEIR Model with Control Intervention: Ebola as a Case Study , 2006, Biometrics.